Shockwave Buys Neovasc, Hoping Reducer Angina Device Complements Coronary Lithotripsy
Executive Summary
Shockwave, which markets lithotripsy technology to treat calcified vascular disease, will pay about $100m upfront and up to $47m more in potential milestones to buy Neovasc, the Vancouver, BC-based developer of the Reducer device to treat angina.
You may also be interested in...
FDA Approves Shockwave Coronary Intravascular Lithotripsy System
Shockwave Medical received a FDA premarket approval for its C2 coronary intravascular lithotripsy-based calcification remedy and announced its 2020 results, in line with expectations.
Neovasc Maintains Investor Confidence Despite FDA Struggles; Sells $72M In Stock
Despite a recent unfavorable FDA advisory panel for its Reducer coronary sinus device, some investors showed their faith in the Canadian company by buying 36 million shares.
Minute Insight: Abbott Rolls Out Navitor Next-Gen TAVR System To Catch Up To Medtronic And Edwards
Navitor is an upgraded version of Abbott’s Portico TAVR system with a better fabric cuff and large curved aortic “cells” to reduce the risk of injury to the native valve.